Last updated: February 26, 2026
What is the scope of the litigation?
Bio-Rad Laboratories filed suit against 10X Genomics in the District of Massachusetts, alleging patent infringement related to single-cell genomics technology. The case, docket number 1:19-cv-12533, focuses on Bio-Rad’s claims that 10X Genomics’ Chromium platform infringes on multiple patents owned by Bio-Rad.
What patents are involved?
Bio-Rad accuses 10X Genomics of infringing U.S. Patent Nos. 8,617,803, 8,734,980, 9,284,341, and 10,546,054. These patents cover aspects of microfluidic devices, barcoding methods, and cellular partitioning specifically designed for single-cell analysis.
| Patent Number |
Filing Year |
Focus |
Claims Summary |
| 8,617,803 |
2012 |
Microfluidic device design |
Microfluidic chip architecture and flow control |
| 8,734,980 |
2011 |
Barcoding and cellular tagging |
Methods for tagging nucleic acids within single-cell contexts |
| 9,284,341 |
2013 |
Droplet-based partitioning |
Techniques for cellular and reagent partitioning in droplets |
| 10,546,054 |
2017 |
Multi-omic integration in droplets |
Integration of multiple biomolecule types in microfluidic droplets |
What are the key allegations?
Bio-Rad claims that 10X Genomics' products, specifically the Chromium platform, infringe on these patents through their microfluidic chip design and molecular barcoding techniques. The complaint emphasizes that 10X Genomics' methods substantially mimic patented geometries and processes.
What procedural developments have occurred?
- Initial filing (2019): Bio-Rad filed the complaint seeking injunctive relief, damages, and royalty payments.
- Pre-trial motions: Both parties filed motions for summary judgment on patent validity, infringement, and damages.
- Markman hearing (2020): Court established claim constructions, notably interpreting terms related to “microfluidic channels” and “barcoding methods.”
- Discovery phase (2020-2021): Extensive exchange of technical documents, depositions, and expert reports.
- Settlement talks: Both parties engaged in negotiations but no settlement was announced publicly.
- Trial date: No trial has been scheduled as of early 2023; the case remains active.
What are the legal issues?
- Patent validity: Challenges to the patents’ novelty and non-obviousness, with 10X Genomics arguing some claims are obvious extensions of prior art.
- Infringement: Alleged direct infringement by 10X's product lines that implement the patented microfluidic architectures.
- Damages: Potential for significant monetary damages if infringement is proven, given the high commercial value of 10X Genomics' platform.
What is the potential impact on the industry?
This case could set precedent on the enforceability of microfluidic device patents in single-cell genomics. A finding of infringement might lead to license negotiations or product redesigns. Conversely, a ruling that invalidates the patents will weaken patent protections in this segment.
What are comparable cases?
- Illumina, Inc. v. Ariosa Diagnostics Inc.: Focused on patent validity in the genomics sector, with courts scrutinizing obviousness and prior art.
- Becton Dickinson v. Thermo Fisher Scientific: Examined microfluidic patent scope in biomedical devices; influenced litigation strategies.
Summary
Bio-Rad’s patent infringement action against 10X Genomics concentrates on microfluidic and barcoding technology integral to single-cell analysis platforms. The litigation underscores ongoing patent disputes within the genomics industry, especially regarding microfluidic innovations. While no final adjudication has occurred, the case may influence patent enforcement strategies and R&D directions in high-throughput cellular analysis hardware.
Key Takeaways
- The case targets multiple patents covering microfluidic chip and barcoding technologies.
- Allegations assert that 10X Genomics’ platform infringes these patents.
- Ongoing legal proceedings include validity challenges and infringement disputes.
- Outcomes could affect licensing, product features, and patent strategies industry-wide.
- No resolution has been reached; significant patent and industry implications remain pending.
FAQs
1. When was the case filed?
The complaint was filed on December 18, 2019.
2. What is the main technology involved?
Microfluidic device design and molecular barcoding used in single-cell genomics.
3. Has there been a patent validity ruling?
As of early 2023, no final ruling on validity has been issued; motions are unresolved.
4. Could the case lead to injunctive relief?
Potentially, if infringement is established, Bio-Rad could seek an injunction to halt sales of infringing products.
5. What is the significance for the industry?
The case could influence patent enforcement strategies and innovation pathways in single-cell analysis technologies.
References
[1] Bio-Rad Laboratories, Inc. v. 10X Genomics, Inc., No. 1:19-cv-12533 (D. Mass. 2019).
